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First series of minimally invasive, robot-assisted
tracheobronchoplasty with mesh for
severe tracheobronchomalacia
Richard Lazzaro, MD,a Byron Patton, MD,a Paul Lee, MD,b Jason Karp, MD,c Efstathia Mihelis, PA-C,a
Sohrab Vatsia, MS,a and Samuel Jacob Scheinerman, MDa
ABSTRACT
Objective: Tracheobronchomalacia is a progressive, debilitating disease with
limited treatment options. Open tracheobronchoplasty (TBP) is an accepted
surgical option for management of severe tracheobronchomalacia. This study
examined the outcomes of the first reported series of robot-assisted TBP (R-TBP).
Methods: We retrospectively reviewed the records of patients with clinical
suspicion for tracheobronchomalacia who had dynamic computed tomography
scan and subsequent R-TBP from May 2016 to December 2017.
Results: Four hundred thirty-five patients underwent dynamic computed
tomography scan for suspicion of tracheobronchomalacia. Of this group,
42 patients underwent R-TBP. In the surgery group, the median age was 66 years
(interquartile range, 39-72 years) and there were 30 women (71%). Respiratory
comorbidities included asthma (88%) and chronic obstructive pulmonary disease
(52%). The median operative time was 249 minutes (interquartile range,
266-277 minutes). Median hospital length of stay was 3 days (interquartile range,
2-4.75 days), and there were 19 postoperative complications (11 minor and
8 major). There were no mortalities at 90 days. Comparison of preoperative and
postoperative pulmonary function testing demonstrated improvement in forced
expiratory volume at 1 second by 13.5% (P ¼ .01), forced vital capacity by
14.5% (P<.0001), and peak expiratory flow rate by 21.0% (P<.0001). Quality
of life questionnaires also showed improvement with 82% reporting overall
satisfaction with the procedure.
Conclusions: R-TBP can be performed with low morbidity and mortality.
Early follow-up reveals significant improvement in pulmonary function testing
and high patient satisfaction when compared with preoperative baseline.
Long-term follow-up is needed to demonstrate the durability of R-TBP and
substantiate its role in the management of patients with symptomatic, severe
tracheobronchomalacia. (J Thorac Cardiovasc Surg 2019;157:791-800)
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Improvement of pulmonary function tests following
robot-assisted tracheobronchoplasty.
Central Message
Robotic tracheobronchoplasty for adult
tracheobronchomalacia is safe; associated
with significant improvement in FEV1, FVC,
and PEFR; and can further the benefits of
open tracheobronchoplasty.
Perspective
Robotic tracheobronchoplasty is safe and
associated with early improvement in FEV1,
FVC, and PEFR. The robot-assisted
platform is ideal for the minimally invasive
surgical approach to tracheobronchomalacia.
The surgical procedure requires a standard
approach to dissection that can be taught and
learned by a wide breadth of thoracic surgeons.
The robotic platform is ideal to further the
adoption of surgical treatment of tracheobron-
chomalacia in adults.
See Editorial Commentary page 801.
Tracheobronchomalacia (TBM) is characterized by
weakness of the trachea and 1 or both of the mainstem
bronchi. TBM commonly manifests through an acquired
etiology; that is, secondary to chronic obstructive
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pulmonary disease (COPD), relapsing polychondritis,
tracheotomy, or chronic inhaled corticosteroid use.1-3
Pathologically, severe TBM leads to atrophy of the
posterior airway membrane and complete or near-
complete collapse of the anterior tracheobronchial cartilage
wall, ultimately attenuating dynamic airflow.4 As a result,
patients exhibit dyspnea, persistent cough, and are often
predisposed to pneumonia and other respiratory infections.5
Refractory and intractable symptoms may prompt further
investigation with dynamic imaging and bronchoscopy
leading to a diagnosis of TBM. However, because there
are no published guidelines for clinical identification of
TBM, a high degree of suspicion is needed. It has been esti-
mated that the overall incidence of TBM is 5% to 10% in
the general population, and a cutoff of 70% narrowing
on forced expiration has been recognized to diagnose
TBM.6 Severe TBM has been defined as complete or
near-complete collapse of the trachea, demonstrated by
functional bronchoscopy and dynamic computed tomogra-
phy (CT) scanning.7
Treatment of the disease consists of tracheobronchial stent-
ing of the airway and open tracheobronchoplasty (O-TBP).
These techniques stabilize the airway in patients by restoring
more normal airway geometry.8,9 Both self-expanding
metallic stents and silicone Y stents have been studied
previously with indication of some temporary relief of
symptoms. Expandable metal stents preserve mucociliary
function and can be placed with relative simplicity but may
be difficult to remove secondary to granulation tissue in
inflamed airways.10 Silicone Y stents may improve dyspnea
and quality of life3; however, complications such as mucus
plugging, foreign body irritation with cough, and stent-
related infections may occur.10 Stenting has been established
as a short-term surrogate for O-TBP and may help determine
candidates for surgical treatment. However, stents are not
effective as a long-term solution.11
The goal ofO-TBP is to achieve stabilization of the trachea
and both mainstem bronchi by posterior membrane plication
and splinting of the posterior cartilage using polypropylene
mesh.7 TBP is performed through right posterolateral thora-
cotomy, with exposure of the intrathoracic trachea, bilateral
main bronchi, and bronchus intermedius. Mesh is sutured to
the posterior membrane and cartilage in a partial thickness
fashion to avoid entering the airway lumen, thereby restoring
normal airway geometry and plication of the redundantmem-
brane.7 Wright and colleagues8 demonstrated significant
improvement in forced expiratory volume at 1 second
(FEV1), forced vital capacity, and peak expiratory flow rate
in 14 patients using this technique. However, the largest pub-
lished series of 63 patients by Gangadharan and colleagues7
showed no improvement in FEV1. This series also showed
improvement in quality of life, respiratory symptoms, and
functional status, but the authors acknowledge that these sub-
jective measures may have confounding variables making
definitive conclusions difficult. Consequently, ‘‘the search
for an objective measurement of improvement remains the
Holy Grail of intervention for TBM.’’11
Robot-assisted thoracoscopic surgery provides a
stereoscopic, high-definition view with enhanced degrees
of freedom and scaled motion. Multiple studies show low
morbidity andmortality for other robot-assisted thoracic pro-
cedures such as lobectomy.12,13 In 2015, Lazar and
colleagues14 substantiated the feasibility of robotic-assisted
bilateral bronchoplasty for the treatment of TBM. The bene-
fits (eg, decreased morbidity) of minimally invasive surgery
have been elucidated over the past decades through
numerous publications. The rationale for robot-assisted
TBP (R-TBP) is that application of minimally invasive tech-
nology to an established, but complex, open technique may
allow the surgeon to perform the same operation with
decreased mortality associated with minimally invasive sur-
gery. The purpose of this study was to evaluate patient demo-
graphic characteristics, complications, and surgical
outcomes of minimally invasive R-TBP for the treatment
of symptomatic patients with severe TBM.
PATIENTS AND METHODS
This retrospective study was approved by the Northwell Health
Institutional Review Board. Study data were collected and managed using
Research Electronic Data Capture electronic data capture tools hosted at
Northwell Health.15 Research Electronic Data Capture is a secure,
web-based application designed to support data capture for research
studies, providing an intuitive interface for validated data entry, audit trails
for tracking data manipulation and export procedures, automated export
procedures for seamless data downloads to common statistical packages,
and procedures for importing data from external sources.
Inclusion criteria were: all patients with clinical suspicion of TBMwho
underwent dynamic CT scan from May 2016 to December 2017 at a
Northwell Health facility. TBM was defined as 50% collapse of the
airway by dynamic CT. The charts of all patients with evidence of TBM
on dynamic CT scan were reviewed. Patients were excluded from this study
if they were unable to complete dynamic CT scanning or were no longer
alive at time of chart review.
Severe TBM was defined as>90% collapse on awake bronchoscopy.
R-TBP inpatient and outpatient charts were reviewed to assess for any
complications within the first 90 days after surgery and were graded based
Abbreviations and Acronyms
6MWT ¼ Six-Minute Walk Test
COPD ¼ chronic obstructive pulmonary disease
CT ¼ computed tomography
FEV1 ¼ forced expiratory volume at 1 second
GERD ¼ gastroesophageal reflux disease
O-TBP ¼ open tracheobronchoplasty
PFT ¼ pulmonary function test
R-TBP ¼ robot-assisted tracheobronchoplasty
SGRQ ¼ St George’s Respiratory Questionnaire
TBM ¼ tracheobronchomalacia
VATS ¼ video-assisted thoracic surgery
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on Clavien-Dindo classification.16 Preoperative and postoperative
pulmonary function testing, St George’s Respiratory Questionnaire17
(SGRQ), and Six-Minute Walk Test18 (6MWT) data were collected and
analyzed for the surgical group. A 5-point postoperative Likert scale was
used to assess subjective change in cough, shortness of breath, ability to
manage respiratory infections, ability to move air with breathing, and
overall satisfaction with the procedure. No surgical patients were excluded
from this study.
Diagnosis
Pulmonary medicine team members evaluated each patient for
symptoms consistent with TBM, including progressive dyspnea, chronic
severe cough, and recurrent pulmonary infections. Comorbid conditions
were actively managed by primary care physicians as well as specialists,
and included gastroesophageal reflux disease (GERD), sinus conditions,
COPD, asthma, and obstructive sleep apnea. Asthma19 and COPD20
were defined in accordance with American Thoracic Society guidelines,
GERD was diagnosed by symptomatology of esophageal injury secondary
to gastric content reflex, and cardiovascular disease encompassed
arrhythmia, coronary artery disease, and heart failure. Active smokers
were counseled on smoking cessation. If symptoms persisted despite
maximal medical therapy, patients were referred for dynamic airway
screening CT scan, which was performed according to a protocol. This
protocol included a full chest CT scan on inspiration followed by
ultra-low-dose CT during exhalation and cine images attained during
forced exhalation. A diagnosis of TBM or findings suggestive of TBM
was rendered by Board-certified radiologists. Patients with radiographic
findings of 50% collapse of the tracheobronchial tree were referred for
thoracic surgical evaluation. Patients with persistent, severe symptoms
underwent awake bronchoscopy. Severe symptoms were defined as those
that negatively influence a patient’s everyday life, frequent hospitalizations
with pulmonary infection, or escalating medications such as steroids with
no improvement. Bronchoscopic findings demonstrating>90% collapse of
the airway on exhalation was used to confirm the diagnosis of severe TBM
(Figure 1).
Clinical Suspicion
of TBM Dynamic CT Scan > 50% Collapse
Medical
Management
> 90% Collapse-
Severe TBM
Thoracic Surgery
Evaluation
Bronchoscopy
Offered
lntractable
Symptoms
(not tolerable)
TBP Operable?
Yes
YesNo
No
No
NoNo
Yes
Yes
Yes Yes
No
FIGURE 1. Evaluation and management of patients suspected of having tracheobronchomalacia (TBM). Patients with clinical suspicion of TBM are
referred for dynamic computed tomography (CT) scan according to established Northwell Health Imaging protocol. Patients who exhibit collapse of the
tracheobronchial tree 50% on CT are evaluated by a member of the thoracic surgery team. Surgical candidates for robot-assisted tracheobronchoplasty
(TBP) who demonstrate persistent, severe symptoms are offered bronchoscopy. If bronchoscopic findings confirm>90% collapse of the airway, and if the
airway is deemed operable for relief of intractable symptoms, patients undergo robot-assisted TBP. If patients do not meet any of these surgical inclusion
criteria, they are treated by medical management.
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Stent Trial
Patients with intractable symptoms who were diagnosed with severe
TBM by dynamic CT scan and awake bronchoscopy, underwent
tracheobronchial stent trial. The initial 11 patients underwent stent trial
with self-expanding nitinol stents of the trachea, bronchus intermedius,
and left main bronchus. Eight of 11 patients had improvement in symptoms
and underwent R-TBP 2 weeks after stent explantation. The remaining 3
patients had increased cough and noncardiac chest pain during the stent
trial that resolved following stent removal. One of these 3, and the last of
our stent trial patients, required stent removal 48 hours following initial
placement secondary to fever and hypotension, which resolved soon after
removal. However, after recovery from the stent trial, symptoms returned,
and all 3 patients elected to undergo R-TBP for progressive, symptomatic,
severe TBM. Due to these stent complications, the ability of a stent trial to
assess symptom improvement and help patient selection was determined to
be inadequate and no further stent trials were performed on subsequent
patients. Patients with severe symptoms not responsive to medical
therapies and severe TBM on bronchoscopy (>90% collapse) were offered
R-TBP.
Surgical Management
The surgical approach requires general anesthesia, double lumen
endotracheal intubation, and robot-assisted video-assisted thoracic surgery,
utilizing 4 robotic arms/ports with 1 additional 12-mm port for the
assistant. The patient is positioned in the left lateral decubitus position
with the da Vinci XI (Intuitive Surgical Inc, Sunnyvale, Calif) robot
brought in from the right side of the patient and the boom rotated clockwise
to position it over the head of the patient. The robot is docked to the ports
and carbon dioxide insufflation (to aid resorptive atelectasis) to a pressure
of 8 is initiated as instruments are inserted. With gentle traction, utilizing a
sponge with the fourth arm of the robot, the deflated right lung is retracted
anteriorly and medially. The azygos vein is dissected and divided to
facilitate exposure of the entirety of the intrathoracic trachea and mainstem
bronchi. Bipolar energy is used for dissection, which is carried out anterior
to the esophagus from the level of the thoracic inlet to the inferior
pulmonary vein. With continued gentle anteromedial traction on the
deflated right lung, the subcarinal space is visualized. Routinely, the
contralateral superior pulmonary vein is also identified. Subcarinal lymph
nodes are either dissected away from the airway or resected to expose the
cartilaginous rings of the left and right bronchi. Posterior splinting left
main bronchoplasty is performed with a 53 1.4 cm polypropylene braided
mesh. Three rows of partial thickness sutures (4-0 Vicryl, RB -1; Ethicon
Inc, Somerville, NJ) are utilized to secure the mesh to the posterior
cartilage. The lateral sutures are placed several mm away from the edge
of the mesh and placed partial thickness through the posterior cartilage
and back through the mesh. Sutures are placed from distal to proximal,
and each individual suture incorporates a distinct separate bronchial
cartilage. These sutures are tied, securing the mesh to the airway.
Horizontal mattress sutures are then placed through the mesh, followed
by posterior membrane, and then back through the mesh. The middle
row of horizontal mattress sutures pleat the posterior membrane to the
mesh. Before securing the pleating sutures, the medial sutures are placed
through the mesh, partial thickness through the medial posterior cartilage
and back through the mesh. Cartilaginous sutures are tied before securing
the pleating sutures. Occasionally, proximal bronchoplasty requires 4 rows
of sutures. The effective bronchial width of the mesh is 10 mm. An
8 3 2.2 cm polypropylene mesh is secured to the trachea with 4 rows of
sutures for an effective tracheal width of 16 mm. Sutures are placed several
millimeters away from the edge of the mesh and placed partial thickness
through the posterior cartilage of the left aspect of the trachea, and back
through the mesh. Sutures are placed from proximal to distal, and each
individual suture incorporates a distinct separate tracheal cartilage. These
sutures are tied, securing the mesh to the airway. Two columns of
horizontal mattress sutures are then placed through the mesh, followed
by posterior membrane, and then back through the mesh. Horizontal
mattress sutures are used for the middle 2 rows to more effectively pleat
the posterior membrane. Before securing the pleating sutures, the medial
sutures are place through the mesh, partial thickness through the
right-sided posterior tracheal cartilage and back through the mesh.
Cartilaginous sutures are tied before securing the pleating sutures. Repair
of the right mainstem bronchus and bronchus intermedius is similar to
repair of the left mainstem bronchus with the same size mesh and effective
bronchial width. Care must be taken to avoid narrowing the right upper lobe
bronchus. All sutures are placed at partial thickness to avoid potential air
leak and risk of contamination of the mesh. Bronchoscopy is performed
before completion of the procedure to assess the repair as well as patency
of all lobar and segmental bronchi. A solitary 24 Fr chest tube is placed. For
pain control, intercostal nerve blocks as well as intravenous acetaminophen
and ketorolac were used. The patients are extubated in the operating room
and transferred to the intensive care unit (Video 1).
Statistical Analysis
Continuous data are summarized as median and interquartile range
(IQR). Preoperative and postoperative measurements of pulmonary
function tests (PFTs), 6MWTs, and SGRQ quality of life questionnaires
were compared using Wilcoxon signed-rank paired analyses, given the
nonparametric data distribution.
RESULTS
Between September 2016 and November 2017, 435
patients underwent dynamic CT scan for clinical suspicion
of TBM. Of this group, 183 had>50% collapse by CT. One
hundred forty-five were evaluated by thoracic surgery and
42 consecutive patients underwent R-TBP for severe
symptomatic TBM (Figure 2).
The median age of the surgical group was 66 years
(IQR, 59-72 years) with 30 female patients (71%). The
median body mass index was 29 (IQR, 27-34). There
were 2 patients (4%) with a recent history of smoking
(<1 year before R-TBP). Patients exhibited respiratory
comorbidities, including asthma (88%) and COPD (52%)
and also presented concurrently with GERD (85%),
VIDEO 1. Robotic tracheobronchoplasty technique. Video available at:
https://www.jtcvs.org/article/S0022-5223(18)32935-0/fulltext.
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hypertension (52%), diabetes mellitus (26%), and
cardiovascular disease (14%). Six patients (14%) had prior
chest surgery, including ipsilateral video-assisted thoracic
surgery (VATS) right upper lobectomy, open bilobectomy,
VATS left lower lobectomy, VATS left upper lobe
trisegmentectomy, left VATS wedge resection, and
coronary artery bypass surgery. The median operative
time was 249 minutes (IQR, 226-277 minutes) and no blood
transfusions were necessary. Chest tubes were removed at a
median of 1 day after surgery (IQR, 1-1 day). The median
hospital length of stay was 3 days (IQR, 2-4.75 days) and
median length of intensive care unit stay was 1 day (IQR,
1-2 days).
There were a total of 19 postoperative complications
within the first 90 days, including 11 minor complications
(26%) and 8 major complications (19%) as defined by
Clavien-Dindo classification schema.16 Four complications
were Grade I (1 pneumothorax and 3 subcutaneous
emphysema) that required no intervention. Seven Class II
complications were all infectious in etiology (4 bronchitis
and 3 pneumonia) and treated with antibiotics. Of the major
complications, 4 were Class IIIa (2 chest tube insertions for
pneumothorax and 2 infraclavicular blowholes for
subcutaneous emphysema) and did not require general
anesthesia for intervention. Two complications were Grade
IIIb and required general anesthesia for intervention. One
patient had VATS evacuation of hemothorax after chest
tube insertion on postoperative day 2. Although not within
the first 90 days, another patient required revision surgery
for persistent symptoms on postoperative day 125. Two
patients (4%) had unplanned return to an intensive care
unit (Grade IV): 1 for bronchoscopy and the other for
arrhythmia (tachy-brady syndrome). There were no
reintubations, no tracheostomies, and no mortalities at
90 days.
Forty patients had complete sets of preoperative and
postoperative PFTs in the surgical group. Postoperative
PFTs were performed at a median of 4 months (IQR,
2-6 months). The median preoperative percent predicted
FEV1 was 62.50% (IQR, 51.25%-82.00%) and was
76.00% (IQR, 55.25%-91.75%) after surgery (P ¼ .01)
(Figure 3, A). The median preoperative percent
435 Patients
Dynamic CT 
Scan
252 Patients
< 50% Collapse
38 Patients
Declined Further
Evaluation
29 Patients
Tolerable
Symptoms
16 Patients
Inoperable
12 Patients
Declined
Bronchoscopy
2 Patients
Lost to Follow-up
7 Patients
Awaiting
Bronchoscopy
37 Patients
No Surgery
20 Patients
< 90% Collapse
Medical
Management
14 Patients
> 90% Collapse
Chose Medical
Management
3 Patients
Awaiting Surgery
183 Patients
≥ 50% Collapse
145 Patients
Evaluated by
Thoracic Surgery
66 Patients
No
Bronchoscopy
79 Patients
Bronchoscopy
42 Patients
> 90% Collapse
Underwent TBP
FIGURE 2. Lenox Hill Northwell Health tracheobronchomalacia (TBM) program. Four hundred thirty-five patients underwent dynamic computed
tomography (CT) scan for clinical suspicion of TBM. Of this group, 183 had>50% collapsed, as observed by CT. One hundred forty-five patients were
evaluated by members of the thoracic surgery team and 42 consecutive patients underwent robot-assisted tracheobronchoplasty (TBP) for severe
symptomatic TBM.
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predicted forced vital capacity was 69.50% (IQR, 59.25%-
82.25%) and improved to 84.00% (IQR, 70.50%-96.25%)
following operation (P<.0001) (Figure 3, B). The median
preoperative percent predicted peak expiratory flow rate
was 60.00% (IQR, 52.00%-73.25%) and rose to 81.00%
(IQR, 67.25%-101.75%) after surgery (P < .0001)
(Figure 3,C). The percent change from preoperative pulmo-
nary function per patient is illustrated in Figure 4.
In addition to undergoing pulmonary function testing
perioperatively, 17 patients underwent 6MWT at a median
of 5 months (IQR, 2-7 months) postoperatively; the
median preoperative distance was 378.66 m (IQR,
255.11-389.63 m) and 380.49 m (IQR, 297.91-389.02 m)
postoperatively (P ¼ .08). Additionally, 15 patients
completed SGRQ quality-of-life measures at a median of
2 months (IQR, 1-4 months) postoperatively. The median
1
–50
–25
0
25
50
75
100
Pe
rc
en
t C
ha
ng
e 
(%
)
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Patient Number
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
FVC
PEFR
FEV1
FIGURE 4. Percent change in percent predicted forced vital capacity (FVC), peak expiratory flow rate (PEFR), and forced expiratory volume in 1 second
(FEV1) by patient. Forty patients had complete sets of preoperative and postoperative PFTs. Percent predicted FEV1 (green bars), FVC (blue bars), and
PEFR (red bars) were collected at a median of 4 months (interquartile range, 2-6 months) postoperatively.
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FIGURE 3. Median percent predicted lung function before and after robot-assisted tracheobronchoplasty. A, Forced expiratory volume in 1 second
(FEV1). B, Forced vital capacity (FVC). C, Peak expiratory flow rate (PEFR). The median preoperative percent predicted FEV1 was 62.50% (interquartile
range [IQR], 51.25%-82.00%) and was 76.00% (IQR, 55.25%-91.75%) after surgery (P ¼ .01). The median preoperative percent predicted FVC was
69.50% (IQR, 59.25%-82.25%) and improved to 84.00% (IQR, 70.50%-96.25%) following operation (P<.0001). The median preoperative percent
predicted PEFR was 60.00% (IQR, 52.00%-73.25%) and rose to 81.00% (IQR, 67.25%-101.75%) after surgery (P<.0001). The boxes indicate the
IQR, with the upper boarder and lower boarder of the box indicating the upper and lower quartiles, respectively. Whiskers represent the minimum and
maximum values. The central line demonstrates the median (n ¼ 40 patients per group).
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preoperative SGRQ score was 65.28 (IQR, 51.08-84.06)
and decreased to 46.22 (IQR, 26.36-56.34) following
R-TBP (P ¼ .002). Notably, the minimum clinically
important difference defines the minimum change in a
patient derived score that is meaningful for the patient
and is generally agreed to be 4 units for SGRQ.21
Although long-term patient follow-up is presently
ongoing, 35 patients completed a 5-point (Likert scale) sur-
vey assessing satisfaction with the R-TBP procedure
at a median of 13 months postoperatively (IQR,
8.0-15.5 months). Twenty-four of 33 patients (72%) who
had symptomatic cough reported subjective improvement,
19 of 33 patients (57%) who had symptomatic shortness of
breath reported subjective improvement, 17 of 25 patients
(68%) reported subjective improvement of their ability to
manage respiratory infections, 25 patients (71%) reported
subjective improvement of their ability to move air with
breathing, and 29 patients (82%) reported satisfaction with
the overall results of the procedure.
DISCUSSION
This study shows that R-TBP is feasible and can be
performed with significant improvement in PFTs and high
overall patient satisfaction. The robotic platform allows
emulation of an open approach by giving the surgeon
improved visualization, flexibility of wristed instruments,
and the precision to place dozens of sutures without injury
to the airway through scaled motion. The significant
increase in 3 PFT parameters indicates that the technical
aspects of the repair are not compromised with the
minimally invasive approach. In addition, 82% of patients
reported overall satisfaction with the results. Although the
interpretation of subjective data are difficult due to
confounding variables, it is encouraging that many patients
also had objective improvement.
In the 42 patients who underwent R-TBP, there were 11
minor complications and 8 major complications with only
1 patient requiring bronchoscopy postoperatively and
another undergoing VATS for hemothorax after bedside
chest tube insertion. One patient was discharged on
postoperative day 2 but had revision 4 months after
surgery for recurrent TBM. All patients were discharged
home. There were no reintubations, no tracheostomies,
and no deaths. Postoperative pain was controlled with
anti-inflammatory medications and minimal narcotics.
Aggressive pulmonary toilet and ambulation likely aided
in avoiding pulmonary complications.
This studyhas limitations, including its retrospective nature
and incomplete measurement of subjective change in symp-
toms by SGRQ. On a postoperative survey, most patients re-
ported overall satisfaction, but not all symptoms improved
to the same degree. Chronic cough was most improved with
shortness of breath the least. Currently, we enroll all patients
with TBM referred for thoracic surgery in a prospective study
that includes not only PFTs, but also subjectivemeasures such
as SGRQ. Because all operationswere performed over a short
period of time, long-term follow-upwill be necessary to estab-
lish the durability of the repair. In addition, all operationswere
performed at a single institution and similar outcomes would
need to be reproduced to validate the technique and to estab-
lish it as a standard operative approach.
The future of TBP seems bright. TBM is a vastly
underdiagnosed condition that has remained virtually
untreated for decades. The prevalence of TBM has been esti-
mated to be as high as 10% in the general population,22 but re-
view of data from the Society of Thoracic Surgeons General
Thoracic Surgery Database23 shows only 262 tracheoplasties
performed from 2002 to 2017. There are still many challenges
to overcome regarding the diagnosis and management of
TBM. First and foremost is patient selection for TBP.Most pa-
tients clearly experience dramatic relief in symptoms with a
corresponding rise in PFTs. However, a minority of patients
do not have significant benefit, but reasons are often unclear.
Development of a prediction model may aid in selection
when more data are available. Further investigation is needed
to explicate the role of stents, optimal mesh size, and custom-
ized repair for unique malacic airway geometry. More
advanced imagingmay assist with operative planning and bet-
ter noninvasive diagnosis. Although a minimally invasive
approach may expand the options for patients with this com-
plex disease, patient selection is still paramount and critical
to optimal outcomes.
Webcast
You can watch aWebcast of this AATSmeeting presentation
by going to: https://aats.blob.core.windows.net/media/18Apr
30/25ABC%202.General%20Thoracic%20SS/S69%20-
%20Part%201/S69_1_webcast_020125204.mp4.
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Discussion
Dr Abbas Abbas (Philadelphia, Pa).
Thank you, Dr Lazzaro. I want to
commend you on the impressive series
you and your coauthors have presented
here. This study not only describes the
first consistent minimally invasive
modality to this operation of posterior
tracheoplasty in adults, but also is
among the largest series, period, for this operation. Perhaps
among the most important findings in your study is the
proof of concept that this difficult operation can be done
consistently in a minimally invasive fashion and with safe
and excellent results.
I agree with you that this disease is probably vastly
underdiagnosed. With so many patients who potentially
have severe tracheobronchomalacia, the value of
tracheoplasty has already been established in other studies.
However, these patients are often too frail or sick to undergo
a lengthy thoracotomy and, therefore, the ideal operation
would be a minimally invasive option. It is also not
surprising that the entire Society of Thoracic Surgeons
database has only 262 patients in a 15-year period. You
have done 20% of that number in just 18 months.
This brings me to my first question. I was impressed by
the extremely high number of patients that your institution
has screened for tracheobronchomalacia using dynamic
computed tomography (CT) scan: 435 in 18 months.
What was the impetus for this approach, which is certainly
much higher than most other hospitals? Was it based on an
institutional decision of your group to start actively
screening for this disease?
Dr Lazzaro (New York, NY). It was
based on a case report. About 5 years
ago we saw someone who met the
criteria for tracheobronchoplasty and
would not have been a candidate for
an open approach and was declined
open surgery. At that time we
performed we used a minimally
invasive approach, we reported it, it is several years later
(4.5 years in fact), and he is well. That led to a conversation
with a pulmonologist in our system. We work in New York,
we have more than 10 million patients, we have 22
hospitals, and we have pulmonologists who have been in
practice for more than 2 decades who have been able to
take care of patients on a longitudinal basis. Over that
time, they have recognized that their patients have become
progressively symptomatic and less responsive to
treatment. So a casual conversation about tracheobroncho-
malacia led to asking if I scan some patients who are falling
down, who are clinically deteriorating, would you be
willing to see them?
I don’t think that any surgeon wakes up and says, this is
the case that I want to do, but I was impressed with how
impaired they were, and if we could replicate the excellent
work of open tracheobronchoplasty, we might be able to
further the adoption of it. So it’s saying yes as opposed to no.
Dr Abbas. It seems that all patients with >50%
narrowing on dynamic CT were automatically referred for
surgical evaluation. Why did your group choose 50% rather
than 90% as the cutoff for referral?
Dr Lazzaro. There were studies done in the early 1990s
that demonstrated a normal person has approximately a
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34% reduction in the cross-sectional area during a
bronchoscopy or dynamic CT scan. So if you used>50%
collapse, I think only 1 patient who was normal had that.
So in general that is the definition of excessive dynamic
airway collapse. Mild tracheobronchomalacia is 70% to
80% collapse, 80% to 90% is moderate tracheobronchoma-
lacia, and severe tracheobronchomalacia is>90%.
When you do the dynamic CT scans, it is not necessarily
on the forced exhalation, maximum exhalation that you see
the maximum reduction in the cross-sectional area. Sowhen
we saw the screening tests demonstrate more than normal,
we elected to evaluate them.
We didn’t bronchoscope every patient. A patient needed
to have clinical symptoms consistent with the radiographic
diagnosis that would lead us down the path of a dynamic
bronchoscopy.
Dr Abbas. So you found a discrepancy between the
dynamic CT degree of narrowing and what you saw on
bronchoscopy?
Dr Lazzaro. I can’t say we found a discrepancy on all of
the studies, but when you do a dynamic CT scan, the patients
are coached several times and the technician has to capture
the scan. So a dynamic CT can be very good to rule in, but if
it’s not captured at the right time of the expiratory cycle, it
may underassess the severity of the airway collapse.
Dr Abbas. My final question is about the role of
preoperative pulmonary function, which actually appeared
only mildly depressed or close to normal. So in addition,
the postoperative increase, although statistically
significantly improved, was mild or modest. It doesn’t
seem that your group really placed much emphasis on the
pulmonary function tests. So why did you use that as a
parameter to check postoperatively rather than repeating a
dynamic CT or bronchoscopy?
Dr Lazzaro. Although the dynamic CTs can be done
with low radiation exposure, we use CT scans and bron-
choscopies to evaluate patients with persistent symptoms.
I think that’s important. When I look at the literature of
open tracheobronchoplasty, the goal has often been quoted
as a patient who has symptomatically improved with an
improvement in the quality of life. In fact, someone has
even said that the holy grail is to obtain an objective
measure of improvement. I think the peak expiratory flow
is something that makes sense to me in terms of seeing an
improvement when people have significant airway collapse.
There are not many procedures available to thoracic
surgeons. Relief of airway obstruction; decortication; and,
at least in the short term, robotic tracheobronchoplasty
can potentially improve pulmonary function tests.
So we did look at symptomatic improvement and,
consistent with what is reported in the literature, have
seen between 70% and 80% improvement in cough, the
subjective feeling that the patient could breathe better and
clear secretions better. I think as we are moving forward
with our registry, we are looking at the improvement not
only in pulmonary function but also in comorbid conditions.
Very frequently, a patient will come back and say that his or
her sleep apnea is better. Well, that makes sense, because it
was probably intrathoracic as opposed to something
cervical in the pharynx. We see that diabetes (anecdotally)
and hypertension is better, and that might be just a reset of
adrenal access and maybe they are no longer struggling to
breathe. It has been a phenomenal several years of looking
at this illness.
Dr Abbas. Thank you, Richard. I enjoyed your talk.
Dr Scott Swanson (Boston, Mass).
Rich, that was phenomenal, really
groundbreaking. Great results and
nice work. Two quick questions: You
may have mentioned this, but is there
a learning curve and how steep is it?
and, Do you have any insight into the
complications that you are going to
see or might see and how to avoid those if you start to really
generalize this operation? I could imagine because this is
going to change theway people recover from this andmakes
it easier that we could slide into doing this more easily for
less-severe disease. In this meeting there is going to be a
presentation on redos.
Dr Lazzaro. That’s a great question. Thank you,
Dr Swanson. I think there are technical aspects to the proced-
ure that all of us in this room can do: dissect, cut, and sew. I
think that not everybody has the same number of years or
cases for robotic experience. I think really the key is to
become facile with the robot so you can learn how to intro-
duce the robot to give you the visualization to perform the
open tracheobronchoplasties that Drs Grillo, Mathisen,
Wright, Gangadharan, and Bueno all performed. Our learning
curve is really not something where it’s 20 procedures. I think
that the learning curve was 5 years ago learning the robot.
When I look at our first 10 cases, wewere really concerned
about the placement of the sutures and not going full
thickness, and then we gradually learned that you are
magnified and you are able to see thewidth of your instrument
and the width of the needle. The posterior membrane is 2- to
3- to 4-mm thick, and so you are placing those not from 18 in
away, but tangentially in the same plane as the membrane. So
it’s just getting comfortable with a new approach to perform
the same procedure.
Dr Daniel L. Miller (Marietta, Ga).
Rich, an incredible series. I see that
you have abandoned preoperative stent
placement, and that’s what we have
always used in our algorithm of doing
these patients, because if the stent
didn’t improve them for whatever
period of time, 10 to 14 days, we did
not proceed. I just wonder why you have gone that route.
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Dr Lazzaro. I think there is no satisfactory stent. I think
stent patients can tell you that they feel better, but they can
get dislodged, obstructed, and cause more problems, and a
negative stent trial does not necessarily mean that that
patient won’t improve. So it was a surrogate to see if
someone improved. You would feel more justified in putting
them through a posterior lateral thoracotomy with its
associated risks.
Dr Miller. I was surprised about your lack of
postoperative bronchoscopy requirement. Usually when
we do them as an open technique, they have so much
bronchorrhea that we are bronching them 2 or 3 times a
day for that first 3 to 5 days, and you only had that occur
once.
Dr Lazzaro. Our patients are sitting in a chair several
hours postoperation and walking in the intensive care unit,
frequently the chest tube is taken out a day later, and I think
the facts that they did not have an epidural, they are not
taking narcotics, and they are being managed with regional
blocks administered in the operating room allows us to get
them up and moving, and we really haven’t seen that.
Dr Miller. Outstanding series.
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